Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
Pratley
Richard E
RE
University of Vermont, College of Medicine, USA.
D000284:Administration, Oral; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000451:nursing; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000819:agonists / Q000502:physiology; D005934:Glucagon / Q000187:drug effects / Q000502:physiology; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D054795:Incretins / Q000502:physiology / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology; D008875:Middle Aged; D009722:Nurse Practitioners; D018579:Patient Selection; D011320:Primary Health Care
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon